glp-1 small molecule agonist glp-1_analogs [TUSOM Oral GLP-1-Based Therapeutics in the

The study emphasizes the necessity of more investigation to comprehend the processes behind these impacts on fracture risk and bone metabolism ( It has been demonstrated that GLP-1 agonists significantly increase the mass of the femur and vertebrae ( In individuals with T2DM, the risk of fractures was assessed using a network meta-analysis and systematic review to determine the relationship between dipeptidyl peptidase-4 inhibitors (DPP-4i), GLP-1 RAs, and sodium-glucose cotransporter-2 inhibitors (SGLT-2i)

[DOI] [PubMed] [Google Scholar] 91.Alba M, Yee J, Frustaci ME, Samtani MN & Fleck P Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study

One datapoint in GLP-1MK-801 was omitted due to extensive food spillage

Alpha-cell paracrine signaling in the regulation of beta-cell insulin secretion

Thus, supporting the cardiovascular safety of these drugs and not necessarily their observed benefits